Modifying Clinical Studies Midstream Can Be Done, With Caution, FDA Says
This article was originally published in The Gray Sheet
Adaptive device clinical trials, where study is designed in anticipation of midstream changes, are the focus on a new FDA draft guidance. Adaptive trials can reduce the duration and cost of a study without undermining its integrity, but the practice should be applied with caution, FDA says.
Register for our free email digests: